Tagged with BIA

UK Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record.   The UK’s exit from the European Union looms large over all British industries, including pharmaceuticals and biotech. Unsurprisingly, therefore, UK…

Saudi Arabia Saudi Arabia is aiming to become a more attractive investment destination for multinational pharma companies through economic development projects that facilitate ease of doing business. Not stopping there, the Kingdom has a bold ambition to become a pharma hub for the entire Middle East region.    Saudi Arabia has the…

Pharma Market Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech Republic is in second place, followed by Romania and Hungary Made with Visme Infographic Maker     The CEE countries that exported…

China Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which recently concluded Phase III trials in China; and their future plans for an IPO.   We combined US experience and…

Top 10 Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future.   Geoffrey Guy Geoffrey Guy is the chairman and founder…

Spain Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he gives an overview of what differentiates Spain and Labiana in the competitive world of pharmaceutical production.   The old business…

Korea JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of the Korean biopharmaceutical industry to become a global leader in the field.   Our priority is to support the globalization…

Portugal Antonio Portela, seven years into leading the Bial operation in Portugal, shares his views on internationalization and how to maintain a stable company culture when approaching new and diverse markets. He discusses Portuguese market trends, future patent challenges and provides an intriguing insight into running a leading family-owned pharmaceutical company.…

UK Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions that continue to render the life-sciences sector attractive, and how the NHS is well-suited to the advent of big data…

Serbia Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World Bank’s ‘Doing Business’ rankings from 93rd in 2014 to 43rd in 2018. Serbia’s GDP per capita between 2008 and 2016. International comparison of healthcare spending growth and GDP growth between…

Serbia In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three enterprising Serbian companies – Pharmanova, INNventa and Esensa – have found success by stepping up their offering in dietary and other health supplements, as well as cosmetics and…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…